| abstract |
The present invention relates to a compound of formula (1) or a pharmaceutically acceptable acid addition salt thereof:n n n n n n n n n n Wheren n n R 1 to R 4 are independently hydrogen, -CF 3 , -OCF 3 , -OCHF 2 , -OCH 2 F, lower alkyl, lower alkoxy, halogen, hydroxy, phenyl, benzyl, amino, nitro, pyrrole-1- One, lower alkyl-sulfonyl, lower alkyl-sulfanyl, cyano or benzyloxy, orn n n R 2 and R 3 together represent —O— (CH 2 ) 2 —O—, —O—CH 2 —O—, —O— (CH 2 ) 2 —, — (CH 2 ) 3 — or —CH = CH -CH = CH- can be formed;n n n X represents -N =, -N (R 8 )-or -CH =,n n n Y represents -N =, = N-, -N (R 8 )-or -CH =, whereinn n n One of X and Y must be nitrogen;n n n R 5 is Group;n n n R 6 and R 7 independently of one another represent hydrogen, lower alkyl, -C (O) -lower alkyl, hydroxy-lower alkyl, lower alkenyl or -C (O) CH 2 OH, orn n n R 6 and R 7 together with the nitrogen atom are-(CH 2 ) n -,-(CH 2 ) 2 -O- (CH 2 ) 2- , -CH 2 -CH = CH-CH 2- , -CH 2- CH [OC (O) CH 3 ]-(CH 2 ) 2- , -CH 2 -CH [NHC (O) CH 3 ]-(CH 2 ) 2- , -O- (CH 2 ) 3- , -CH 2 -CH (0CH 3 )-(CH 2 ) 2- , -CH 2 -CH (halogen)-(CH 2 ) 2 -,-(CH 2 ) 2 -CH (O-phenyl)-(CH 2 ) 2 -,-(CH 2 ) 2 -N (CHO)-(CH 2 ) 2 -,-(CH 2 ) 2 -N (COCH 3 )-(CH 2 ) 2- , -CH 2 -CH (OH)- Can form (CH 2 ) 3 -,-(CH 2 ) 2 -CH (OH)-(CH 2 ) 2 -or-(CH 2 ) 2 -N (benzyl)-(CH 2 ) 2- ;n n n n represents 3 to 5;n n n R 8 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl,-(CH 2 ) m -O-lower alkyl,-(CH 2 ) m -OH,-(CH 2 ) m -CHF 2 ,-(CH 2 ) m -CH 2 F,-(CH 2 ) m -C (O) -lower alkyl,-(CH 2 ) m -C (O) O-lower alkyl,-(CH 2 ) m -CH (OH) -Lower alkyl,-(CH 2 ) m -CH (OH)-(CH 2 ) m OH,-(CH 2 ) m -C 6 H 5 , wherein the phenyl ring is substituted by lower alkyl, lower alkoxy or hydroxy ),-(CH 2 ) m -C (= CH 2 ) -lower alkyl,-(CH 2 ) m -cycloalkyl,-(CH 2 ) m -CN,-(CH 2 ) m -pyridine- 4-yl,-(CH 2 ) m -pyridin-3-yl or-(CH 2 ) m -pyridin-2-yl;n n n m represents 0-4.n n n These compounds may be useful for the treatment of diseases associated with NMDA (N-methyl-D-aspartate) receptor subtype selective inhibitors. |